Related Experiment Video
Updated: Apr 3, 2026
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
10:33
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
1.3K
Therapies from Fucoidan: An Update.
Janet Helen Fitton1, Damien N Stringer2, Samuel S Karpiniec3
1Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia. Helen.fitton@marinova.com.au.
Marine Drugs
|September 22, 2015
Summary
Fucoidans, sulfated polysaccharides from marine algae, show promise for immune support, cancer inhibition, and fighting pathogens. Ongoing research highlights their potential therapeutic applications.
Area of Science:
- Marine natural products
- Carbohydrate chemistry
- Pharmacology
Background:
- Fucoidans are sulfated polysaccharides abundant in brown algae and echinoderms.
- These compounds possess diverse biological activities, including immune modulation, anticancer, and antimicrobial effects.
- Recent research indicates potential therapeutic or adjunct roles for fucoidans.
Purpose of the Study:
- To review the current understanding of fucoidan bioactivities and applications.
- To discuss the sources, extraction methods, and characterization techniques for fucoidan.
- To highlight the growing research interest and future prospects of fucoidan.
Main Methods:
- Literature review of scientific publications on fucoidan.
- Analysis of studies detailing fucoidan extraction and purification processes.
- Examination of research on fucoidan's biological activities and detection methods.
Main Results:
- Fucoidans exhibit significant immune-modulating, anticancer, and pathogen-inhibiting properties.
- Various marine algae and echinoderm species serve as sources for fucoidan extraction.
- Standardized methods for extraction and characterization are crucial for reproducible results.
Conclusions:
- Fucoidans represent a promising class of biomolecules with substantial therapeutic potential.
- Further research into their mechanisms of action and clinical efficacy is warranted.
- Optimized extraction and characterization are key to unlocking the full potential of fucoidans.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
642
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
642
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
684
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
684
01:29Inflammatory Bowel Disease IV: Pharmacological Management
950
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
950
01:17Drugs for Treatment of Diarrhea-Predominant IBS
885
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
885
01:24Cystic Fibrosis: Management
620
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
620
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
759
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
759